

Christopher P Evans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/299858/publications.pdf>

Version: 2024-02-01

25
papers

950
citations

687363

13
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

1863
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
2	Olaparib-Induced Senescence Is Bypassed through G2â€M Checkpoint Override in Olaparib-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 677-685.	4.1	6
3	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4
4	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
5	Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. <i>Journal of Clinical Oncology</i> , 2021, 39, 13-16.	1.6	9
6	Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6377.	3.3	38
7	Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 134-149.	5.4	55
8	Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2112426.	5.9	2
9	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
10	Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. <i>European Urology</i> , 2021, 80, 519-520.	1.9	0
11	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	3.9	6
12	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 1793.	7.1	10
13	Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6064-6074.	7.0	16
14	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	7.1	87
15	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
16	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	4.0	30
17	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1708-1718.	4.1	42
18	AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1875-1886.	4.1	51

#	ARTICLE	IF	CITATIONS
19	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>European Urology</i> , 2019, 75, 535-536.	1.9	2
20	Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer. <i>JAMA Oncology</i> , 2019, 5, 171.	7.1	18
21	Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. <i>American Journal of Clinical and Experimental Urology</i> , 2019, 7, 203-214.	0.4	6
22	Development of a stress response therapy targeting aggressive prostate cancer. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	124
23	Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. <i>Rare Tumors</i> , 2018, 10, 203636131878972.	0.6	1
24	Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment. <i>BJU International</i> , 2015, 116, 170-172.	2.5	10
25	Comparative Safety of Endovascular Aortic Aneurysm Repair Over Open Repair Using Patient Safety Indicators During Adoption. <i>JAMA Surgery</i> , 2014, 149, 926.	4.3	19